COMPARISON OF SERUM HOMOCYSTEINE LEVEL IN METFORMIN VERSUS LIBENCLAMIDE TREATED TYPE 2 DM PATIENTS

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

RANJBAR OMRANI GH.H.; ZARE N.; BAZARGAN LARI O.; SAADAT N.; MAHDIZADEH A.R.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Diabetes and Metabolism Year:2005 | Volume:4 | Issue:2 Page(s): 0-0

Download Full-Text

Persian Verion

View:

956

Download:

Cites:

Information Journal Paper

Title

COMPARISON OF SERUM HOMOCYSTEINE LEVEL IN METFORMIN VERSUS LIBENCLAMIDE TREATED TYPE 2 DM PATIENTS

Author(s)

Keywords

DIABETES MELLITUS TYPE 2Q4

HOMOCYSTEINEQ3

METFORMINQ2

GLIBENCLAMIDEQ4

Abstract

Background: Diabetes mellitus is the most common cause of renal failure, blindness, non- traumatic amputation and neuropathy. HOMOCYSTEINE, a sulfurated amino acid, has a close correlation with Methionine and Cysteine. The conversion of Methionine to HOMOCYSTEINE and Cysteine is required coenzymes like vitamin B6, B12 and Folate. The effect of METFORMIN on serum HOMOCYSTEINE level by decreasing vitamin B12 level in patients with type 2 diabetes mellitus was described previously. Methods: This is a prospective clinical trail study among patients with type 2 diabetes mellitus in Shiraz. 76 patients were divided into two groups (38 patients in each group). First group treated with METFORMIN 500-2000 mg/day and the second group treated with GLIBENCLAMIDE 5-20 mg/day with follow up period of at least 6 months. Hb and MCV were used in follow up to detect megaloblastic anemia, indicator of B12 and folate deficiency. Fasting plasma HOMOCYSTEINE level Hb A1C and blood sugar were measured in baseline and at 3 and 6 months follow up periods. Results: There was no significant difference between age, sex, weight, height and BMI and baseline serum profile between the two groups. HOMOCYSTEINE level increased significantly in METFORMIN group at 3 and 6 months(P=0.003 and 0.001 respectively). Mean plasma HOMOCYSTEINE level after 6 months were 10.98±0.58 µmol/l in METFORMIN and 10.0± 0.88 µmol/l in GLIBENCLAMIDE group, with significant difference between the two groups (P=0.001). Conclusion: METFORMIN increases the plasma HOMOCYSTEINE level. METFORMIN will accumulate highly in gastrointestinal wall and cause malabsorption of vitamin B12, therefore we can conclude that the use of METFORMIN for 6 months can cause vitamin B12 malabsorption and increase in plasma HOMOCYSTEINE level. Increase in plasma HOMOCYSTEINE level was 7.54% in our study that is higher in comparing to the other studies. It can be explained by longer duration of METFORMIN therapy in our study. Rising in HOMOCYSTEINE levels may have detrimental effect on vessels that need further study.

Cites

No record.

References

No record.

Cite

APA: Copy

RANJBAR OMRANI, GH.H., ZARE, N., BAZARGAN LARI, O., SAADAT, N., & MAHDIZADEH, A.R.. (2005). COMPARISON OF SERUM HOMOCYSTEINE LEVEL IN METFORMIN VERSUS LIBENCLAMIDE TREATED TYPE 2 DM PATIENTS. JOURNAL OF DIABETES AND METABOLIC DISORDERS, 4(2), 0-0. SID. https://sid.ir/paper/366980/en

Vancouver: Copy

RANJBAR OMRANI GH.H., ZARE N., BAZARGAN LARI O., SAADAT N., MAHDIZADEH A.R.. COMPARISON OF SERUM HOMOCYSTEINE LEVEL IN METFORMIN VERSUS LIBENCLAMIDE TREATED TYPE 2 DM PATIENTS. JOURNAL OF DIABETES AND METABOLIC DISORDERS[Internet]. 2005;4(2):0-0. Available from: https://sid.ir/paper/366980/en

IEEE: Copy

GH.H. RANJBAR OMRANI, N. ZARE, O. BAZARGAN LARI, N. SAADAT, and A.R. MAHDIZADEH, “COMPARISON OF SERUM HOMOCYSTEINE LEVEL IN METFORMIN VERSUS LIBENCLAMIDE TREATED TYPE 2 DM PATIENTS,” JOURNAL OF DIABETES AND METABOLIC DISORDERS, vol. 4, no. 2, pp. 0–0, 2005, [Online]. Available: https://sid.ir/paper/366980/en

Related Journal Papers